\
&
Contact us
\
&
Contact us
Published on | 1 year ago
ProgrammesThe Innovative Health Initiative (IHI) has announced its plans to pilot a novel, applicant-driven approach to its next call for proposals. As there are still untapped opportunities in IHI's Strategic Research and Innovation Agenda (SRIA), Call 9, which is scheduled for launch in early 2025, will have a much broader scope than previous calls.
Call 9 will welcome proposals covering any aspect of the SRIA. Proposals will still have to adhere to the philosophy of IHI. They will have to: address an unmet public health need; require a large-scale, ambitious, cross-sector, public-private partnership; have clearly-described impacts on society, the economy and science; take account of the pre-competitive nature of IHI projects.
From a procedural point of view, IHI call 9 will be a standard, single-stage call for proposals. Applicants will have to ensure that half of their project’s costs are covered by in-kind contributions from IHI’s industry members and (if relevant) IHI contributing partners.
Read more about upcoming IHI Call 9 here.
Interested to participate? Register now for the following events organised by IHI for the upcoming Call 9:
Questions? E-mail applicants@ihi.europa.eu
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Culture and society EIT New European Bauhaus
EIT Culture & Creativity has opened its first funding calls as an implementing partner of the New European Bauhaus (NEB) Academy, the learning and innovation infrastructure of the NEB. These two calls offer a total of €6 million to support circular fashion and skills development for the transformation of Europe’s lived environme... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
